Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy.

Regulatory T cells (Tregs) are abundant in tumor tissues, raising a question of whether immunosuppressive tumor-infiltrating Tregs (TI-Tregs) can be selectively depleted or functionally attenuated to evoke effective anti-tumor immune responses by conventional T cells (Tconvs), without perturbing Treg-dependent immune homeostasis in healthy organs and causing autoimmunity. Here, we review current cancer immunotherapy strategies, including immune checkpoint blockade (ICB) antibodies against CTLA-4 and PD-1 and discuss their effects on TI-Tregs. We also discuss approaches that exploit differentially regulated molecules on the cell surface (e.g., CTLA-4) and intracellularly (e.g., T cell receptor signaling molecules) between TI-Tregs and Tconvs as well as their dependence on cytokines (e.g., IL-2) and metabolites (e.g., lactate). We envisage that targeting TI-Tregs could be effective as a monotherapy and/or when combined with ICB antibodies.

• Publication year

  2023

• Venue

  Cancer Cell

• Publication date

  2023-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ccell.2023.02.014PMID 36917950
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein.

  2022cited by this paper
• SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling

  2022cited by this paper
• Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody

  2022cited by this paper
• Construction of a T cell receptor signaling range for spontaneous development of autoimmune disease

  2022cited by this paper
• Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.

  2022cited by this paper
• Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity

  2022cited by this paper
• PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells

  2022cited by this paper
• Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy

  2022cited by this paper
• Roles of Regulatory T Cell-Derived Extracellular Vesicles in Human Diseases

  2022cited by this paper
• Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy

  2022cited by this paper
• Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody

  2022cited by this paper
• An anti-CTLA-4 heavy chain–only antibody with enhanced Treg depletion shows excellent preclinical efficacy and safety profile

  2022cited by this paper
• Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy

  2022cited by this paper
• PD-L1 – PD-1 interactions limit effector regulatory T cell populations at homeostasis and during infection

  2022cited by this paper
• Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma

  2022cited by this paper
• An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy

  2022cited by this paper
• Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy

  2022cited by this paper
• PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity

  2022cited by this paper
• Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells

  2022cited by this paper
• CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory

  2022cited by this paper
• Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment

  2021cited by this paper
• Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1low and immune desert-like mouse tumors

  2021cited by this paper
• CCR4 as a Therapeutic Target for Cancer Immunotherapy

  2021cited by this paper
• Anti–PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells

  2021cited by this paper
• Role of hypoxia in inhibiting dendritic cells by VEGF signaling in tumor microenvironments: mechanism and application.

  2021cited by this paper
• Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells

  2021cited by this paper
• TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer

  2021cited by this paper
• Pannexin 1 channels facilitate communication between T cells to restrict the severity of airway inflammation.

  2021cited by this paper
• Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners

  2021cited by this paper
• The Curcumin Analog GO-Y030 Controls the Generation and Stability of Regulatory T Cells

  2021cited by this paper
• The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity.

  2021cited by this paper
• Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas

  2021cited by this paper
• Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity.

  2021cited by this paper
• CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function

  2021cited by this paper
• A tumor-specific mechanism of Treg enrichment mediated by the integrin αvβ8

  2021cited by this paper
• Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models

  2021cited by this paper
• Programmed cell death-1 (PD-1) pathway deficiency enhances autoimmunity leading to dacryoadenitis of mice.

  2021cited by this paper
• The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies

  2021cited by this paper
• Lipid signalling enforces Treg cell functional specialization in tumours

  2021cited by this paper
• Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy

  2021cited by this paper
• CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors

  2021cited by this paper
• Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells.

  2021cited by this paper
• The diversity and breadth of cancer cell fatty acid metabolism

  2021cited by this paper
• FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets.

  2020cited by this paper
• Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as Single Agent and in Combination with Checkpoint Inhibitors.

  2020cited by this paper
• An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells.

  2020cited by this paper
• Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells

  2020cited by this paper
• Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

  2020cited by this paper
• Immune‐checkpoint molecules on regulatory T‐cells as a potential therapeutic target in head and neck squamous cell cancers

  2020cited by this paper
• TIGIT enhances CD4+ regulatory T‐cell response and mediates immune suppression in a murine ovarian cancer model

  2020cited by this paper
• Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4

  2020cited by this paper
• Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies

  2020cited by this paper
• Regulatory T Cells and Human Disease.

  2020cited by this paper
• Cryo-EM Reveals Integrin-Mediated TGF-β Activation without Release from Latent TGF-β.

  2020cited by this paper
• Homeostasis and transitional activation of regulatory T cells require c-Myc

  2020cited by this paper
• Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.

  2020cited by this paper
• PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance

  2020cited by this paper
• Metabolic support of tumor-infiltrating regulatory T cells by lactic acid

  2020cited by this paper
• Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule

  2020cited by this paper
• CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity

  2020cited by this paper
• Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies

  2020cited by this paper
• The Role of GITR/GITRL Interaction in Autoimmune Diseases

  2020cited by this paper
• The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

  2020cited by this paper
• VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers

  2019cited by this paper
• Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control

  2019cited by this paper
• Disruption of the CCL1-CCR8 axis inhibits vascular Treg recruitment and function and promotes atherosclerosis in mice.

  2019cited by this paper
• Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.

  2019cited by this paper
• Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses

  2019cited by this paper
• Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?

  2019cited by this paper
• PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

  2019cited by this paper
• Essential and non-overlapping IL-2Rα-dependent processes for thymic development and peripheral homeostasis of regulatory T cells

  2019cited by this paper
• α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

  2019cited by this paper
• Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion

  2019cited by this paper
• The Intersection between Tumor Angiogenesis and Immune Suppression

  2019cited by this paper
• CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

  2019cited by this paper
• Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.

  2019cited by this paper
• PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.

  2019cited by this paper
• Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells

  2019cited by this paper
• Effects of interleukin-2 in immunostimulation and immunosuppression

  2019cited by this paper
• Etomoxir Actions on Regulatory and Memory T Cells Are Independent of Cpt1a-Mediated Fatty Acid Oxidation.

  2018cited by this paper
• Cancer immunotherapy using checkpoint blockade

  2018cited by this paper
• Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

  2018cited by this paper
• Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

  2018cited by this paper
• Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

  2018cited by this paper
• Emerging Functions of Regulatory T Cells in Tissue Homeostasis

  2018cited by this paper
• Extrathymically Generated Regulatory T Cells Establish a Niche for Intestinal Border‐Dwelling Bacteria and Affect Physiologic Metabolite Balance

  2018cited by this paper
• PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface

  2018cited by this paper
• Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth

  2018cited by this paper
• CD226 opposes TIGIT to disrupt Tregs in melanoma.

  2018cited by this paper
• Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

  2018cited by this paper
• Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody

  2018cited by this paper
• Identification and functional analysis of heterogeneous FOXP3+ Treg cell subpopulations in human pancreatic ductal adenocarcinoma.

  2018cited by this paper
• CCR8+FOXp3+ Treg cells as master drivers of immune regulation

  2017cited by this paper
• The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

  2017cited by this paper
• Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

  2017cited by this paper
• Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

  2017cited by this paper
• Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments.

  2017cited by this paper
• Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor

  2017cited by this paper
• Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.

  2017cited by this paper
• CCR5-Dependent Homing of T Regulatory Cells to the Tumor Microenvironment Contributes to Skin Squamous Cell Carcinoma Development

  2017cited by this paper

• Immunotherapy-driven remodeling of the tumor immune microenvironment: Spatiotemporal heterogeneity and multidimensional dynamics.

  2026cites this paper
• Regulatory T Cell Heterogeneity in the Steady State and Tumor.

  2026cites this paper
• Metabolic crosstalk between cancer and stromal cells: Implications for precision oncology.

  2026cites this paper
• Reactive sulfur species as emerging immunomodulators: mechanistic insights and therapeutic prospects

  2026cites this paper
• MITA/STING-driven CD38 induction in Siglec-Flow macrophages promotes regulatory T cell survival and non-small cell lung cancer progression.

  2026cites this paper
• Tertiary lymphoid structures correlate with reduced recurrence risk and enhanced antitumor immunity in esophageal squamous cell carcinoma with pathologic non-complete response to neoadjuvant chemoimmunotherapy

  2026cites this paper
• Activated CD38+ mast cells promote gastric cancer progression by suppressing CD8+ T cell cytotoxic activity through adenosine metabolism.

  2026cites this paper
• Identification and validation of AFAP1L1 as an immune-related prognostic biomarker in clear cell renal cell carcinoma.

  2026cites this paper
• Longitudinal scRNA-seq analysis reveals molecular features of T cell exhaustion linked to anti-PD-1 response in hepatocellular carcinoma

  2026cites this paper
• CD168 in lung adenocarcinoma: prognostic relevance, immune feature associations, and MAPK/ERK pathway enrichment

  2026cites this paper
• Vessels encapsulating tumor clusters promote noninvasive metastasis of hepatocellular carcinoma by shaping an immunosuppressive microenvironment

  2026cites this paper
• Identification of key genes and therapeutic targets in bladder cancer using electrochemical sensors and comprehensive bioinformatics analysis: key regulatory factors of POSTN, EFEMP1, and SULF1

  2026cites this paper
• Prediction of tumor-infiltrating lymphocytes through habitat radiomics and exploration of response mechanisms in neoadjuvant immunochemotherapy-treated lung cancer

  2026cites this paper
• A Biomimetic Microparticle Disrupting the Intracellular/Extracellular pH Homeostasis of Tumor Cells for Cancer Chemo-Immunotherapy.

  2026cites this paper
• Rethinking Immunotherapy Biomarkers in Mesothelioma: Immune Imbalance and Genomic Co-Alterations.

  2026cites this paper
• Deficiency of SMARCB1 drives an immunosuppressive microenvironment in meningioma

  2026cites this paper
• Shaping Immunotherapy Through the Tumor Microenvironment: Translational Perspectives.

  2026cites this paper
• Spatial single-cell multi-omics characterization of the tumor microenvironment heterogeneity by HER-2 expression status in gastric cancer : Author list.

  2026cites this paper
• Tumor-infiltrating lymphocytes demonstrate potent anti-tumor efficacy and synergize with PD-1 blockade in bladder cancer.

  2026cites this paper
• Structurally-optimised HPV16 E7/E6 mRNA–LPP mediates dose-sparing efficacy via tumour microenvironment reprogramming

  2026cites this paper
• Microbiome‐urothelium crosstalk in bladder cancer: From dysbiosis to clinical translation

  2026cites this paper
• Mechanisms and strategies for reversing NK cell exhaustion in tumor immunotherapy.

  2026cites this paper
• Paediatric Solid Tumour Vaccines: Current Processes, Prevailing Challenges and Future Perspectives.

  2026cites this paper
• Synergistic cell death pathways in gastrointestinal tumor immunotherapy: molecular mechanisms, metabolic reprogramming, and clinical translation

  2026cites this paper
• Targeting HSPB1 inhibits tumor growth and abrogates Treg-mediated tumor immunosuppression.

  2026cites this paper
• Molecular and cellular remodeling of the colorectal tumor microenvironment using nanoparticles

  2026cites this paper
• The immunobiology and therapeutic potential of regulatory T cells in autoimmune diseases and allergic diseases

  2026cites this paper
• Prognostic immunological implications of OX40L expression in the tumor microenvironment of melanoma

  2026cites this paper
• Ultrasound stimulation generates peroxynitrite synergistic chemotherapy with multifunctional targeted nanoparticles for the treatment of lung cancer

  2026cites this paper
• Self-Assembled Carrier-Free Nanomedicines Potentiate Chemo-Photothermal Immunotherapy by Overcoming Prostaglandin E2-Mediated Immunosuppression.

  2026cites this paper
• Advances in the development of personalized neoantigen therapies.

  2026cites this paper
• Identification of immune-related prognostic biomarkers in lung squamous cell carcinoma microenvironment

  2026cites this paper
• An Immune-privileged niche mediates immunotherapy resistance in esophageal carcinoma

  2026cites this paper
• Identifying Therapeutic Targets for Triple-Negative Breast Cancer using a Novel Mathematical Model of the Tumor Microenvironment

  2026cites this paper
• Dissecting the role of epigenetic regulation in oral squamous cell carcinoma microenvironment: mechanisms and therapeutics

  2026cites this paper
• Targeting senescent cells in aged adipose tissue induced by ovarian cancer with the NF-κB inhibitor quercetin and resveratrol impedes the growth and metastasis of ovarian cancer.

  2026cites this paper
• IgE, anti-IgE therapy, and regulatory T cells: new paradigms in allergic inflammation.

  2026cites this paper
• T‐Cell Immunity and Lung Cancer

  2026cites this paper
• Biomaterial-mediated reactive oxygen species regulation for Cancer immunotherapy: Mechanisms and applications

  2026cites this paper
• Differences in the expression profiles of m6A-related genes and the prognostic role in immunotherapy for lung adenocarcinoma patients

  2026cites this paper
• Regulatory T Cells in Ovarian Cancer: Insights into Cancer Immunotherapy.

  2026cites this paper
• Proliferative T-regulatory cells as a biomarker for immune checkpoint inhibitor efficacy in nasopharyngeal carcinoma: a new frontier.

  2025cites this paper
• Breaking down physical barriers: strategies to improve lymphocyte infiltration for effective neoantigen-based therapies

  2025cites this paper
• SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy

  2025cites this paper
• Regulatory T cells in the tumour microenvironment

  2025cites this paper
• Methotrexate exerts antitumor immune activity and improves the clinical efficacy of immunotherapy in patients with solid tumors.

  2025cites this paper
• Co‐assembled Manganese‐CpG Nanoliposomes for Enhanced Immunotherapy against Colon Cancer Stem Cells

  2025cites this paper
• Single‐cell insights into the role of T cells in B‐cell malignancies

  2025cites this paper
• Adjusting the scope of natural killer cells in cancer therapy

  2025cites this paper
• Mitigating radioresistance mechanisms by polymer-lipid manganese dioxide nanoparticles enhances immunogenic cell death and antitumor immune response to facilitate abscopal effect in breast tumor models

  2025cites this paper
• Recent advances in regulatory immune cells: exploring the world beyond Tregs

  2025cites this paper
• Multi-omics pan-cancer analysis of monocyte to macrophage differentiation-associated (MMD) and its significance in hepatocellular carcinoma

  2025cites this paper
• Integrating Mendelian randomization and multi-transcriptomic analyses to unveil the genetic association risk of regulatory T cell-mediated free cholesterol and gastric cancer

  2025cites this paper
• Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling

  2025cites this paper
• Temporal and Context-Dependent Requirements for the Transcription Factor Foxp3 Expression in Regulatory T Cells

  2025cites this paper
• Immunometabolism of regulatory T cells in cancer

  2025cites this paper
• Inducible protein degradation reveals inflammation-dependent function of the Treg cell lineage-defining transcription factor Foxp3

  2025cites this paper
• Bispecific targeting of 4-1BB and CCR8 boosts antitumor immunity via Ti-Treg depletion and CD8+ activation

  2025cites this paper
• Stemness-driven clusters in ovarian cancer: immune characteristics and prognostic implications

  2025cites this paper
• The tumor microenvironment’s role in the response to immune checkpoint blockade

  2025cites this paper
• Immune Checkpoint Inhibition for Hepatocellular Carcinoma, Cholangiocarcinoma, and Combined Hepatocellular-Cholangiocarcinoma

  2025cites this paper
• Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer

  2025cites this paper
• Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors

  2025cites this paper
• Piezo-catalytic immunotherapy: mechanisms and feasibility in cancer treatment

  2025cites this paper
• The Role of Tregs in the Tumor Microenvironment

  2025cites this paper
• Regulatory T Cells in Tumor Microenvironment: Therapeutic Approaches and Clinical Implications

  2025cites this paper
• The role of exosomes in bladder cancer immunotherapy

  2025cites this paper
• Development of a machine learning-derived programmed cell death index for prognostic prediction and immune insights in colorectal cancer

  2025cites this paper
• Machine learning developed regulatory T cells-related signature for prognosis and immunotherapy benefit in oral squamous cell carcinoma.

  2025cites this paper
• Mechanisms of tumor-associated macrophages promoting tumor immune escape.

  2025cites this paper
• Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade

  2025cites this paper
• PD-L1 Expression in NSCLC: Clouds in a Bright Sky

  2025cites this paper
• Carbon‐ion irradiation together with autophagy inhibition and immune checkpoint inhibitors protect against pancreatic cancer development in mouse model

  2025cites this paper
• Exploiting regulatory T cells (Tregs): Cutting-edge therapy for autoimmune diseases.

  2025cites this paper
• Discovery of Dual PD-L1/HDAC3 Inhibitors for Tumor Immunotherapy.

  2025cites this paper
• Advances in research on flavonoids in tumor immunotherapy (Review)

  2025cites this paper
• Combination therapy with immune checkpoint inhibitors in colorectal cancer: Challenges, resistance mechanisms, and the role of microbiota.

  2025cites this paper
• Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models

  2025influential citation
• Immunocytes in the tumor microenvironment: recent updates and interconnections

  2025cites this paper
• Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit.

  2025cites this paper
• Comprehensive systems biology analysis reveals splicing factor contributions to cutaneous melanoma progression

  2025cites this paper
• Palmitoylation of GPX4 via the targetable ZDHHC8 determines ferroptosis sensitivity and antitumor immunity

  2025cites this paper
• Activation of pyroptosis and immunogenic cell death by targeted liposomal cisplatin for enhanced chemo-immunotherapy for osteosarcoma

  2025cites this paper
• CD38-mediated metabolic reprogramming promotes the stability and suppressive function of regulatory T cells in tumor

  2025cites this paper
• Molecular insights and treatment innovations: Advancing outcomes in acute myeloid leukemia with myelodysplasia‑related changes (Review).

  2025cites this paper
• FCN3可作为肺鳞癌预后及免疫治疗的潜在生物标志物

  2025cites this paper
• ACVR2A attenuation impacts lactate production and hyperglycolytic conditions attracting regulatory T cells in hepatocellular carcinoma

  2025cites this paper
• PCIF1 drives oesophageal squamous cell carcinoma progression via m6Am‐mediated suppression of MTF2 translation

  2025cites this paper
• Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity.

  2025cites this paper
• Suppressor of cytokine signaling 2 modulates regulatory T cell activity to suppress liver hepatocellular carcinoma growth and metastasis

  2025cites this paper
• The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming.

  2025cites this paper
• Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse

  2025cites this paper
• Vps34-orchestrated lipid signaling processes regulate the transitional heterogeneity and functional adaptation of effector regulatory T cells

  2025influential citation
• Turn cold tumors hot by reprogramming the tumor microenvironment

  2025cites this paper
• Association of Immune Cell Phenotypes With Oral Cancer: A Two-Sample Mendelian Randomisation Study

  2025cites this paper
• A D–π–A featured type-I photosensitizer with NIR-II fluorescence emission for imaging-guided synergistic PDT and PTT cancer therapy

  2025cites this paper
• Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation

  2025cites this paper
• PF-08046032: A novel, investigational CD25-directed antibody-drug conjugate optimized for selective depletion of regulatory T cells in advanced malignant tumors.

  2025cites this paper
• Thioredoxin: a key factor in cold tumor formation and a promising biomarker for immunotherapy resistance in NSCLC

  2025cites this paper
• Alginate sulfated polysaccharide TGC161 exhibits antitumor activity via suppression of STING activation-mediated T-cell apoptosis

  2025cites this paper